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A subset of poor-prognosis medulloblastoma has genomic amplification of MYC. MYC regulates glutamine
metabolism in multiple cellular contexts. We modified the glutamine analog 6-diazo-5-oxo-l-norleucine (DON)
to mask its carboxylate and amine functionalities, creating a prodrug termed JHU-083 with increased oral
bioavailability. We hypothesized that this prodrug would kill MYC-expressing medulloblastoma. JHU-083
treatment caused decreased growth and increased apoptosis in human MYC-expressing medulloblastoma
cell lines. We generated a mouse MYC-driven medulloblastoma model by transforming C57BL/6 mouse
cerebellar stem and progenitor cells. When implanted into the brains of C57BL/6 mice, these cells formed large
cell/anaplastic tumors that resembled aggressive medulloblastoma. A cell line derived from this model was
sensitive to JHU-083 in vitro. Oral administration of JHU-038 led to the accumulation ofmicromolar concentrations
of DON in the mouse brain. JHU-083 treatment significantly increased the survival of immune-competent animals
bearing orthotopic tumors formed by the mouse cerebellar stem cell model as well as immune-deficient animals
bearing orthotopic tumors formed by a human MYC-amplified medulloblastoma cell line. These data provide
pre-clinical justification for the ongoing development and testing of orally bioavailable DON prodrugs for use in
medulloblastoma patients.
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Medulloblastoma is the most common malignant brain tumor of
childhood. Though 60% of medulloblastoma patients survive for
at least 10 years, survival varies widely depending on the molecular
genetics of the patient's tumor [43]. RNA expression profiling
and DNA methylation studies have subdivided medulloblastoma
into at least four molecular subgroups: WNT, SHH, Group 3,
and Group 4 [25,33]. The standard treatment for medulloblastoma
is surgical resection of the tumor, radiation and chemotherapy.
This therapy is associated with high morbidity; medulloblastoma
patients often experience cognitive delays, learning disabilities, hearing
loss, increased risk for future malignancies and stroke, endocrine
dysfunction, and cerebellar mutism syndrome [5,15,16,24,39,44]. A
subset of patients within Group 3 have amplification or over-expression
of the MYC proto-oncogene. These patients have among the worst
clinical outcomes of all medulloblastoma patients [2,7]. The relatively
poor prognosis for many medulloblastoma patients and the severe
complications faced by survivors indicate an urgent need for more
effective and less toxic therapies.
MYC regulates a variety of cellular processes, including metab-
olism of both glucose and the amino acid glutamine [9]. Glutamine is
the primary nitrogen source for synthesis of nucleic acids, other
amino acids, and hexosamines. Glutamine can also be used as a
carbon source to replenish TCA cycle intermediates, in a process
called glutaminolysis [27,31]. Many types of MYC-driven cancers
uptake large quantities of glutamine, some to the point of becoming
“addicted” and being unable to survive without glutamine
[10,12,26,47]. MYC regulates the utilization of glutamine by
upregulating genes involved in glutamine uptake and metabolism,
ASCT2, LAT-1 and glutaminase (GLS) [4,18].
The role of glutamine metabolism in MYC-driven medulloblas-
toma is underexplored, but a study by Wilson et al [46] supports
the hypothesis that a subset of medulloblastoma tumors have
elevated glutamine metabolism. Wilson et al non-invasively
measured glutamate levels in the tumors of medulloblastoma
patients using magnetic resonance spectroscopy (MRS). They
found that patients with high-levels of glutamate in their tumors
had much poorer survival than patients with low glutamate levels.
The initial step in glutamine metabolism is the conversion of
glutamine to glutamate by GLS. High levels of glutamate indicate
that glutamine is being metabolized at a high level. Thus, increased
glutamine metabolism is associated with poor-prognosis
medulloblastoma. Because glutamine metabolism is a potential
therapeutic target in other MYC-driven cancers [11,48], we hypothe-
sized that targeting glutamine metabolism in MYC-driven medulloblas-
toma could be a potentially useful strategy in this devastating tumor type.
Methods
2.1 JHU-083
T h e s y n t h e s i s o f J H U - 0 8 3 ( E t h y l
2-(2-Amino-4-methylpentanamido)-DON) was conducted as detailed
by our group previously [37]. For in vitro testing, JHU083 was dissolved
in sterile water; for in vivo studies it was dissolved in sterile PBS buffer.
JHU-083 doses in this paper are given as the DON-equivalent dose. Due
to the presence of the promoities, 1.83 mg of JHU-083 equals 1.0 mg of
unmodified DON.
2.2 Cell Cultureestablished at Duke University [21]. It is grown in MEM media
supplemented with 10% FBS. We generated human neural stem cell
models of MYC-driven medulloblastoma or SV40 immortalized
control cells as described [20]. Our MYC-expressing models
recapitulate Group 3, MYC amplified medulloblastoma by expres-
sion profiling and phenotype [20]. These human neural stem cell
lines grow as neurospheres in "EF" media composed of 30% Ham's
F12, 70%DMEM, 1% antibiotic antimycotic, 2% B27 supplement,
5ug/mL heparin, 20 ng/mL EGF, and 20 ng/mL FGF2 [20]. Those
harboring AKT are grown under puromycin selection. The
MED211 patient derived xenograft was obtained from the Brain
Tumor Resource Lab and is described in [6]. A cell line was derived
from this PDX model by removing tumor tissue from tumor-bearing
mice at the time of sacrifice and passing tumor through a P1000
pipette. Cells were grown in EF media. All cells were verified to be
mycoplasma free by PCR testing. Cell line identity testing was
performed by the Johns Hopkins Genetic Resources Core Facility
and is included in Supplemental Figure 1.2.3 Mouse Medulloblastoma Model
Creation of this model is described in detail in the main body
of the manuscript. The cells are grown in EGF/FGF media made
with a 50:50 mixture of F12:DMEM, but is otherwise identical to
that described above. The R248W-TP53 plasmid (Addgene plasmid
16437) andMYC plasmid (Addgene plasmid 17758) were subcloned
into pWPI (Addgene 12254) [29]. Lentivirus was produced by
transfecting 293T cells with VSV-G envelope plasmid, Δ8.9 gag/pol
plasmid and the plasmid containing the gene of interest as described
in [36] using Fugene (Roche) per manufacturer's instruction. The
supernatant was collected at 48 and 72 h. The collected supernatant
was filtered with a 0.45 micron filter and concentrated overnight at
4’C using 5% PEG 8000 and 150 mM NaCl then centrifuged for
30 minutes at 2000xg. Concentrated virus was stored at -80C in
serum free DMEM until use. Visualization of the distribution of this
model in situ was provided by fluorescence imaging macroscopy
using a dual camera setup for GFP and white light (anatomical)
imaging. The excised brain was illuminated by a SpectraX LED light
source (Lumencor) with emission light captured by an F1.2 80 mm
lens (Nikon), and filtered by a dichroic and low pass filter in an
OptosplitII (Cairn) tube to dual Pixelfly CCDs (PCO). Data was
acquired in Metamorph NX.2.4 Cell growth Assay
Experiments were performed in 96 well plates. Equal numbers of
cells were plated in triplicate for each treatment. 20uL of CellTitre 96
Aqueous One Solution (Promega) was added to each well for every
100uL of media and incubated at 37C for 1 hour. Absorbance was read
at 490 nM on a plate reader. Growth between vehicle and drug treated
cells was statistically analyzed using Student's t-test.2.5 Western blots
Protein was extracted from cell pellets using RIPA buffer and
quantified using a Bradford Assay. Antibody against cleaved-PARP is
from Cell Signaling technologies (#9541). Antibodies against ACTIN
(sc-47778) andMYC (sc-40) are from Santa Cruz Biotechnologies. The
following dilutions were used cleaved-PARP (1:800), ACTIN (1:1000),
and MYC (1:1000). Peroxidase labeled secondary antibodies are from
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quantified using ImageJ.2.6 Cleaved Caspase-3 immunofluorescence
Following 72 h drug treatment, cells were fixed in cytospin fluid and
spun onto glass slides using a cytocentrifuge. Cells were permeabilized
in 0.1% TritonX, blocked in 5% normal goat serum, and incubated
with anti-cleaved caspase-3 antibody diluted 1:400 (Cell Signaling
Technology®, clone 5A1E), followed by a secondary antibody
conjugated to Cy3 diluted 1:500 (Jackson ImmunoResearch). DAPI
was used as a counterstain. Three DAPI and the corresponding Cy3
images were taken for each slide. The number of DAPI and Cy3 positive
cells were counted using Adobe® Photoshop®. For each pair of images,
the percent of Cy3 positive cells was calculated. The average Cy3
positivity was determined by calculating the average of at least three pairs
of images for each treatment. Images were blinded before counting.
Vehicle and drug treated cells were compared by Student's t-test.2.7 Histology
Brains were fixed in 10% buffered formalin for a minimum of 24 h.
The Johns Hopkins Pathology Reference Lab processed tissue for
paraffin embedding and sectioning.2.8 Immunohistochemistry
All IHC staining was performed by the Johns Hopkins Oncology
Tissue services.2.9 Animal Studies
Xenografting was conducted in female mice of a minimum of
6 weeks old. D425MED cells were injected into nude (Nu/Nu) mice.
mNSC DNp53 MYC cells were injected into C57BL/6J mice. Prior
to implantation of cells, animals were anesthetized using a mixture of
10% ketamine and 5% xyaline. A burr hole was made in the skull 1
mm to the right and 2 mm posterior of the lambdoid suture with an
18 gauge needle. The needle of a Hamilton syringe was inserted
2.5 mm into the brain using a needle guard and 100,000 D425MED
cells or 50,000mCBDNp53MYC in 3uL of media were injected into
the cerebellum. JHU-083 was prepared in sterile PBS and
administered by oral gavage in a 100uL bolus twice weekly on
Tuesdays and Fridays. Animals were monitored daily. Individuals
showing signs of neurologic impairment or increased intracranial
pressure were euthanized, brains removed and fixed in formalin.
Survival curves were analyzed using a Log-rank test. For the JHU-083
brain penetration pharmacokinetic study, five athymic nude mice
without brain tumors were given a single DON-equivalent dose of
20 mg/kg JHU-083 dissolved in PBS by oral gavage. Exactly 1 h post
dose, mice were euthanized and the brain regions manually dissected
and flash frozen. Dosing of the animals was staggered to ensure
each animal was only exposed to the drug for 1 h. Extraction and
quantification of DON was performed as described in [49].Figure 1. Chemical structure of 6-diazo-5-oxo-l-norleucine (DON) and
the prodrug JHU-083 (Ethyl 2-(2-Amino-4-methylpentanamido)-DON).2.10. Study Approval
For animal care and anesthesia, “Principles of laboratory animal
care” (NIH publication No. 8623, revised 1985) was followed, using
a protocol approved by the Johns Hopkins Animal Care and Use
Committee, in compliance with the United States Animal Welfare
Act regulations and Public Health Service Policy.Results
3.1 JHU-083
To investigate the utility of glutamine metabolism as a therapeutic
target in MYC-driven medulloblastoma, we utilized JHU-083 (Ethyl
2-(2-Amino-4-methylpentanamido)-DON), a dual promoeity prodrug
of the glutamine analog 6-diazo-5-oxo-l-norleucine (DON). JHU-083 is
orally bioavailable and converts to DON after administration (Figure 1)
[37] [49].
3.2 A cell-based mouse model of MYC-driven medulloblastoma
In addition to utilizing existing patient-derived medulloblastoma cell
lines, we created a novel mouse model using mouse cerebellar stem and
progenitor cells to facilitate in vivo studies in the context of an intact
immune system (Figure 2A). The developing cerebellum was dissected
out of E15 C57BL/6J fetuses, the tissue manually dissociated and
placed in EGF/FGF containing, serum-free cell culture media. These
cells grow as neurospheres. The isolated stem and progenitor cells were
infected with lentivirus bearing human dominant-negative TP53
(DNp53) and human MYC, both of which are associated with
aggressive, poor-prognosis medulloblastoma [7,33]. To generate
subclones, individual neurospheres were manually selected with aid of
a dissecting microscope and expanded before the expression of MYC
and P53was verified by western blot. A representative sub-clone (Figure
2B) shows robust expression of both MYC and TP53. Sub-clones
positive for both oncogenes were injected into the cerebella of 4–6 week
old adult female C57BL/6J mice. If a subclone formed a tumor, the
tumor was implanted into additional mice. This in vivo passaging was
repeated five times. A cell line was generated from the fifth passage. The
tumors formed from mCB DNp53 MYC cells resemble human
anaplastic medulloblastoma, with leptomingeal dissemination (Figure
2C, D) as well as a large cell/anaplastic phenotype Figure 2E, F) [14].
These tumors also showed very robust expression of MYC (Figure 2G)
and TP53 (2H) by IHC, similar to group 3 MYC-driven medullo-
blastoma [20].
3.3 JHU-083 reduces growth of MYC-expressing medulloblas-
toma cell lines
Treatment with 10uM of JHU-083 significantly reduced the growth
of MYC-expressing medulloblastoma models as measured by MTS assay
(Figure 3). All the cell models tested, except for human neural stem cells
immortalized with SV40, express robust amounts of MYC (Figure 3A).
In the patient derived, MYC-amplified cell line D425MED, 10uM
JHU-083 treatment decreased growth by 80% at day 5 of treatment
Figure 2. Development and characterization of a mouse model of MYC-expressing medulloblastoma. A. Diagram showing the steps in
model development. Mouse stem and progenitor cells were isolated from the developing mouse cerebellum and dissociated and
expanded in culture. They were then transduced with lentiviruses containing c-MYC and R248WTP53 (DNp53). GFP + clones were
selected and expanded for further characterization. B. Western blot showing the expression of the introduced oncogenes in the subclone
used in this paper. C.Wholemount fluorescencemicroscopy showing the dorsal view of tumor formed by GFP-positive mCBDNp53MYC
cells, with arrowheads highlighting leptomeningeal spread of GFP + cells. A = anterior P = posterior R = right L = left D. Ventral view
of the same brain, showing extensive involvement of the cerebellumwith spread to the adjacent brain. E. Hematoxylin and eosin (H and E)
staining at low power showing the tumor formed by mCB DNp53 MYC cells (right) adjacent to normal cerebellum (left). F. High-power H
and E showing characteristics of MYC-driven medulloblastoma including abundant mitoses and apoptotic bodies, as well as large
cell/anaplastic phenotype as demonstrated by prominent nucleoli and nuclear wrapping. G. IHC for MYC, showing robust expression
(brown stain). Tumor cells are positive and surrounding normal cells serve as an internal negative control. H. IHC for TP53, showing robust
expression (brown stain). Blood vessel at center left of panel serves as an internal negative control.
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progenitor cells transformed byMYC alone, 10uM JHU-083 treatment
caused a 98% decrease in growth at day 7 of treatment (P = 5.2x10−6).
Human neural stem and progenitor cells transformed with dominant
negative TP53, human telomerase (hTERT), AKT and MYC form
tumors that phenocopy large cell/anaplastic human medulloblastoma
when injected into the cerebella of nude mice. This model also mimics
the expression profile of the C1 subgroup of medulloblastoma, the
subgroup with the poorest prognosis that consists of MYC-expressing
tumors [20]. In two subclones created by the addition of
dominant-negative TP53, hTERT, constitutively-active AKT, and
MYC to human cerebellar stem and progenitor cells, 10uM JHU-083
reduced growth at day 7 by 55% in #2 (P = 3.5x10−5, Figure 3D) and
by 50% in #5 (P = 0.03, Figure 3E). JHU-083 treatment significantly
decreased the growth of mouse cerebellar stem and progenitor cells
transformedwithMYC and dominant-negative TP53 (Figure 3F). 72 h
treatment with 10uM JHU083 lead to an 86% reduction in growth by
day 4 of treatment (P = 7.23x10−6).
3.4 JHU-083 treatment increases apoptosis in MYC-expressing
medulloblastoma cell lines
Treatment with 10uM JHU-083 for 24 h caused an average
3.5-fold increase in the expression of cleaved-PARP as measured
by Western blot in five MYC-expressing medulloblastoma cell lines(Figure 4A), indicating that JHU-083 treatment induces apoptotic cell
death. Treatment with 10uM or 20uM of JHU-083 for 72 hours
similarly caused a significant increase in the percentage of cleaved
caspase-3 positive cells as measured by immunofluorescent staining
(Figure 4B). In the patient-derived cell line D425MED, 10uM
and 20uM of JHU-083 increased the percentage of cleaved
caspase-3 positive cells from 3% to 14% (P = 1.99x10–6) and
29% (P = 1.9x10–7) respectively.
We generated the MED211 cell line from a medulloblastoma
patient-derived xenograft (PDX) tumor. Genetic analysis indicates that
this PDX has MYC amplification and belongs to the G3 medulloblas-
toma subgroup [6]. In MED211 cells, treatment with 10uM or 20uM
JHU-083 increased the percentage of cleaved caspase-3 positive
cells from a baseline level of 22% to 64% (P = 6.2x10–10) and 75%
(P = 2.4x10–11). In human cerebellar neural stem cells transformed
with MYC alone, 10uM and 20uM of JHU-083 increased
cleaved caspase-3 levels from 22% to 32% (P = 0.03) and then to
47% (P = 1.5x10–5). In CB DNp53 hTERT AKT MYC #2, 10uM
JHU-083 and 20uM JHU-083 increased cleaved caspase-3 levels from
8% to 22% (P = 8.2x10−8) and 41% (9.7x10−9). In CB p53 hTERT
AKT MYC #5, 10uM JHU-083 and 20uM JHU-083 increased
cleaved caspase-3 levels from 12% to 30% (P = 0. 0002) and 47%
(P = 2.9x10−5). In the mouse medulloblastoma cell line mCB TP53
MYC, 10uM JHU-083 and 20uM JHU-083 increase cleaved caspase-3
Figure 3. JHU-083 decreases growth of MYC-expressing medulloblastoma cell lines. A. Western blot showing robust MYC expression of
the cell lines used in this manuscript. Human cerebellar stem cells immortalized with SV40 are negative. B-F. MTS growth assays showing
decreased growth of multiple cell lines expressing MYC. Asterisks indicate Pb0.05 by Student’'s t-test compared to similar day control.
Representative graphs shown. Each experiment was repeated a minimum of 3 times with similar results.
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Non-MYC expressing human neural stem cells immortalized with
SV40 were not sensitive to treatment with JHU-083 at 10uM or 20uM
(P N0 .82). These results indicate that JHU-083 induces apoptosis in
MYC-expressing medulloblastoma cell lines and has little effect on
non-MYC expressing cells. To further address the mechanism of
high-MYC cells being sensitive to JHU-083, we determined the
expression of glutaminase (GLS) in our neural stem cell models by
western blot. GLS is regulated by MYC and is a key enzyme governing
the conversion of glutamine to glutamate [8]. We find that cells
transduced with SV40 do not express detectable MYC and do not
express GLS, while cells transduced with MYC alone or additional
oncogenic drivers such as R248WTP53 and activated AKT express
robust levels of GLS (Supplemental Figure 2).
3.5 JHU-083 administration achieves micromolar concentra-
tions of DON in the brain
To determine if DONdelivered by JHU-083 is capable of crossing the
blood–brain barrier, nude mice were administered JHU-083 by oralgavage (20 mg/kg). After 1 hour, the animals were euthanized and the
brains removed. The cortex, cerebellum and brain stem were manually
separated and flash frozen in liquid nitrogen. DON levels in the brain
were subsequently quantified via LC–MS/MS as our laboratory has
previously described [49]. There was no significant difference in
the concentration of DON in the three regions of the brain analyzed
(P = 0.42, one-way ANOVA, n = 5) (Figure 5A). The cerebellum had
an average concentration of 11.3 μΜ of DON. Because 10uM
JHU-083 successfully reduces growth of MYC-expressing medullo-
blastoma cell lines (Figure 3) and induces apoptosis (Figure 4), we
hypothesized that a 20 mg/kg dose of JHU-083 would significantly
extend the survival of animals bearing MYC-expressing medulloblas-
toma tumors.
3.6 JHU-083 extends the survival of animals with MYC-
driven medulloblastoma orthotopic xenografts
Treatment with JHU-083 (20 mg/kg twice weekly) extended the
survival of athymic nudemice bearingD425MEDorthotopic xenografts
from 21 to 28 days, an increase of 29 percent (P = 0.006 by Log-rank
Figure 4. JHU-083 treatment induces cell death by apoptosis. A. 24 h treatment with 10uM JHU-083 causes increased expression of
cleaved-PARP as identified by western blot. Numbers above the blot indicate fold-increase of cleaved-PARP expression compared to
vehicle control. Cleaved-PARP expression was normalized to ACTIN. B. Graph showing that 72 h treatment with 10uM or 20 uM JHU-083
causes a significant increase in cleaved caspase-3 positive cells as determined by immunofluorescence. Asterisk indicates P b 0.05
by Student's t-test compared to vehicle control. N = 3 biological replicates. Bars represent min. to max with each replicate result
represented by a solid dot.
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normal cerebellum.
JHU-083 treatment also successfully extended the survival of
C57BL/6 mice with mCB DNp53 MYC orthotopic xenografts
(Figure 5D). The twice weekly treatment with 20 mg/kg of JHU-083
extended median survival from 16 days to 25 days, an increase of 43
percent (P b 0.0001 by Log-rank test). Figure 5E shows mCB DNp53
MYC tumor adjacent to normal cerebellum.
Discussion
Patients with MYC-expressing medulloblastoma face a grim prognosis.
There are currently no biologically informed therapies available for these
patients. The experiments presented here show the potential for a
metabolic approach to treating this tumor type. The majority of
MYC-positive medulloblastoma tumors fall into the G3/C1 subgroup.
Other studies have shown that many relapsed medulloblastoma tumors
are positive for MYC expression upon relapse, regardless of subgroup
[22], suggesting that targeting MYC-regulated metabolism could
have utility in recurrent medulloblastoma of other subtypes as well as
G3/C1 patients.
A critical aspect of this study is that it compares efficacy of a novel
glutamine antagonist against MYC-driven medulloblastoma models ofboth human and mouse origin and demonstrates a therapeutic response
in both immune deficient and immune competent CNS microenviron-
ments. Our mCB DNp53 MYC cells are derived from C57BL/6J mice
and are rapidly tumorigenic in immune intact animals. TP53mutations
and MYC amplification are not only associated with poor outcomes in
medulloblastoma at diagnosis, they are also the most frequently gained
mutations in relapsed medulloblastoma and both are associated with
aggressive disease phenotypes [22]. Since novel therapeutics will initially
be tested in human patients with relapsed disease and intact immune
systems, the mCB DNp53 MYC cells present an ideal system for
modeling treatment effects in relapsed medulloblastoma. This model
differs from other similar models [35] in that it was established in an
immune intact mouse, utilizes human oncogenes to mimic human
tumor biology in a mouse cell of origin and in that lentiviral vectors
were used to deliver these oncogenes. Since medulloblastoma is an
immunologically “cold” tumor [30], lentivirus was used to decrease the
risk of potentially immunogenic insertional mutagenesis that can occur
with retroviral models [23]. Careful clone selection after in vivo
adaptation has led to the generation of a stable cell line model of
medulloblastoma available for orthotopic use in any transgenic mouse
strain developed on the C57BL/6J background, one of the oldest and
most widely used mouse strains in biomedical science.
Figure 5. JHU-083 improves survival of mice with medulloblastoma tumors. A. 1 hour after a single dose of 20 mg/kg JHU-083, DON
levels are detectable in mouse brain at a range from 8–12 nmol/g. There was no difference in DON levels in the different brain regions.
P = 0.42 by one-way ANOVA, n = 5 brains. Error bars indicate standard deviation. B. Twice weekly 20 mg/kg dosing of JHU-083
significantly extended the survival of athymic nude mice with D425MED tumors. Dashed red line = JHU-083 Solid purple line = vehicle.
P = 0.006 comparing treated vs vehicle control as determined by Log-rank test. N = 5 animals per group. C. H and E image (200X) of
D425MED tumor (left) adjacent to normal cerebellum (right), showing large cell histology associated with group 3 medulloblastoma. D.
Twice weekly 20mg/kg JHU-083 treatment significantly extend the survival of C57BL/6J mice with mCB DNp53MYC tumors. Dashed red
line = JHU-083. Solid purple line = vehicle. P = 0.0001 comparing treated vs vehicle control as determined by Log-rank test. N = 10
animals per group. E) H and E image (200X) of mCB DNp53 MYC tumor (left) adjacent to normal cerebellum (right).
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cient and immune-intact medulloblastoma models. Although dissecting
the effects of DON andDONprodrugs on the adaptive immune system
is beyond the scope of this study, we include an immune-competent
MYC-driven medulloblastoma model to demonstrate that a therapeutic
benefit is preserved in this setting. The dependence of activated
lymphocytes on glutamine is well described and reviewed recently by
Bettencourt and Powell [3]. DON and JHU-083 have a marked
immunosuppressive effect in models of cerebral malaria, decreasing
edema and improving survival of afflicted mice, with corresponding
inhibition of CD-8 T-cell degranulation [19,40]. DON similarly exerts
robust anti-inflammatory effects a viral mouse model of encephalitis
[28]. Interestingly, when DON treatment stopped, the inflammation
resumed and rapidly progressed, leading to the death of mice [28]. Therebound inflammation seen in viral encephalitis suggests that clinical
use of DON might, similar to high-dose cyclophosphamide, alter the
microenvironment in ways that could be manipulated to enhance
the immune response [17]. JHU-083 alters microglial metabolism
by suppressing glutaminase activity [50]. Changes in microglial/
macrophage metabolism may affect the polarity of these cells and alter
the immune microenvironment, contributing to or thwarting an
immune response [34].
These studies indicate that DON/JHU-083 has a profound impact
on both innate and adaptive immunity. Demonstrating that the
anti-tumor effects of JHU-083 are preserved in the presence of an
intact immune system therefore lends important translational
strength to our findings. Many preclinical studies are unable to
include complementary data in immune intact systems due to a lack
Translational Oncology Vol. 12, No. 10, 2019 Hanaford et al. 1321of appropriate models, and this may represent an overall obstacle to
clinical translation. Our immune-intact model presents an opportu-
nity to further investigate the use of novel metabolism-altering
therapies along with immunotherapy in medulloblastoma.
DON is a naturally occurring antibiotic first isolated from Streptomyces
species in the 1950s [13]. It has been used in early phase clinical trials,
including a phase I clinical trial in pediatric patients, however, it has never
been systematically tested against MYC-expressing malignancies [41].
DON is known to target multiple enzymes that use glutamine, including
glutaminase (GLS), asparagine synthetase, and phosphoribosylformylgly-
cinamidine synthase [1,42]. The well-established linkages betweenMYC
and glutamine metabolism in general [8], and the increased mortality
observed in pediatric medulloblastoma patients with evidence of highly
active tumor glutaminemetabolism, [45] led us to hypothesize thatDON
prodrugs would be active against MYC-driven medulloblastoma models.
We found that DON prodrugs were active at concentrations nearly
10-fold lower (10 uM vs 900 uM) than that recently reported for DON
against the non-MYC medulloblastoma cell lines UW228 and DAOY
[32], suggesting that the presence of the MYC proto-oncogene renders
cells highly sensitive to glutamine metabolic inhibition. Indeed, DON
prodrug concentrations that are highly lethal to neural stem cells
engineered to express MYC have no effect on similar cerebellar stem cells
immortalized with SV40. The addition of MYC to neural stem cells is
associatedwith increasedGLS expression, suggesting an increased reliance
on glutamine metabolism downstream of MYC, consistent with prior
reports demonstrating thatMYCbroadly regulates glutaminemetabolism
[18].
Although DON is currently not available for clinical use, the safety
profile of this drug in pediatric patients was superior to that of
traditional chemotherapy. The maximum tolerated dose (MTD) of
DON was not reached in the pediatric phase I trial, with the trial
terminating at a dosage level of 520 mg/m2 administered twice weekly
after enrolling 17 patients [41]. Our effective dose of 20 mg/kg twice
weekly of JHU-083 in mice is equivalent to 2.4 mg/kg in a child or
approximately 60 mg/m2 [38], indicating that our dosing schedule is
significantly below the MTD of DON in pediatric patients. Major
side-effects in the pediatric phase I trial of DON were nausea and
vomiting, which was well controlled with anti-emetic medication [41].
Orally bioavailable DON prodrugs provide a path for clinical
development of glutamine antagonists for use in pediatric patients.
We here demonstrate that oral JHU-083 provides robust delivery of
DON into diverse brain regions in the mouse as well as significant
activity against multiple models of MYC-driven medulloblastoma. We
anticipate that on-going engineering of DON prodrugs will enhance
brain penetration and reduce systemic exposure, thereby further
broadening the therapeutic index.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.tranon.2019.05.013.References
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